JPH0653664B2 - Drug containing psoralen derivative - Google Patents

Drug containing psoralen derivative

Info

Publication number
JPH0653664B2
JPH0653664B2 JP58097768A JP9776883A JPH0653664B2 JP H0653664 B2 JPH0653664 B2 JP H0653664B2 JP 58097768 A JP58097768 A JP 58097768A JP 9776883 A JP9776883 A JP 9776883A JP H0653664 B2 JPH0653664 B2 JP H0653664B2
Authority
JP
Japan
Prior art keywords
methoxypsoralen
active ingredient
ppm
drug
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58097768A
Other languages
Japanese (ja)
Other versions
JPS59222413A (en
Inventor
ジヤン−ジヤツク・グピ−
Original Assignee
ジヤン−ジヤツク・グピ−
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジヤン−ジヤツク・グピ− filed Critical ジヤン−ジヤツク・グピ−
Publication of JPS59222413A publication Critical patent/JPS59222413A/en
Publication of JPH0653664B2 publication Critical patent/JPH0653664B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 本発明は、有効成分として次式： で表わされる５−メトキシプソラレンを含有する薬剤の
用途に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention has the following formula as an active ingredient: The present invention relates to the use of a drug containing 5-methoxypsoralen represented by

この新規薬剤は、本出願人によってフランス国特許第7
7.31719号明細書（1977年１０月２１日出願）中に開示
されており、５−メトキシプソラレンは、他のプソラレ
ン類と比べて非常に毒性が低いため、非常に高い治療指
数を有するものとして記載されている。その特許によっ
て、５−メトキシプソラレンの治療上の投与量は、８−
メトキシプソラレンのそれの５倍まで用いることのでき
ることが明らかにされていてそして、５−メトキシプソ
ラレン２０mgないし300mg／日の経口投薬量を投与し、
続いて1.5ないし１０ジュール／cm2で、Ａ紫外線で毎日
暴露することが提唱されている。This new drug is described by the applicant in French Patent No. 7
It is disclosed in the specification No. 7.31719 (filed on Oct. 21, 1977), and 5-methoxypsoralen is considered to have a very high therapeutic index because it has a very low toxicity compared with other psoralens. Have been described. According to that patent, the therapeutic dose of 5-methoxypsoralen is 8-
It has been shown that up to 5 times that of methoxypsoralen can be used and administers an oral dosage of 20-300 mg / day of 5-methoxypsoralen,
Subsequent daily exposure to A-UV radiation at 1.5 to 10 Joules / cm 2 is proposed.

その特許では、局所投与には、５−メトキシプソラレン
濃度100ppmないし1,000ppmが提唱されている。新規薬剤
の治療活性実験は、乾癬、白斑、異型性湿疹及びキノコ
状真菌症の治療について行った。In that patent, for topical administration, a 5-methoxypsoralen concentration of 100 ppm to 1,000 ppm is proposed. Therapeutic activity experiments of new drugs were carried out for the treatment of psoriasis, vitiligo, atypical eczema and fungal mycosis.

ここでいうキノコ状真菌症は、リンパ腫型の皮膚癌とし
てよく知られており、これはリンパ（真皮及び表皮をめ
だって灌注する間隙液体）中により多く存在するリンパ
球細胞が増殖することを特徴とする。Mushroom fungus is well known as a lymphoma-type skin cancer and is characterized by the proliferation of lymphocyte cells, which are more abundant in the lymph (the interstitial fluid that irrigates the dermis and epidermis). And

前記特許第7731719号明細書中に報告されている臨床実
験は、乾癬にかかっている患者及び皮膚癌にかかってい
る患者の両方について実施しているが、というのは、そ
の２つの疾患に、皮膚細胞の増殖現象が、正常よりも急
速であるという共通の特徴があるからである。このよう
な、細胞の異常増殖という現象は、細胞核中に存在する
デオキシリボ核酸のレベルでのものである。The clinical trials reported in said patent 7731719 are carried out both in patients with psoriasis and in patients with skin cancer, because the two diseases are: This is because there is a common feature that the skin cell proliferation phenomenon is faster than normal. This phenomenon of abnormal cell growth is at the level of deoxyribonucleic acid present in the cell nucleus.

ところで、５−メトキシプソラレンは、紫外線（UV・A r
adiation）の活性化作用下で、DNA分子の２本のヘリッ
クスの各々に固定しそのためそのヘリックスによるあら
ゆる情報伝達が遮断されることによって、タンパク合成
及び細胞増殖が全く停止してしまうことがわかってい
る。正常細胞では、このようなDNAヘリックスの遮断
は、切断または複製といったDNAの自己修正によってす
みやかに妨害される。By the way, 5-methoxypsoralen is
It was found that protein synthesis and cell proliferation are completely stopped by immobilizing each of the two helices of a DNA molecule under the activation of adiation) and thus blocking all signal transduction by the helix. There is. In normal cells, blockade of such DNA helices is quickly prevented by DNA self-correction, such as cleavage or replication.

ところが、乾癬または癌に感染している細胞、すなわち
増加現象が非常に促進されている細胞では、自己修正系
がおいつかない。しかしながらこのような細胞に対し
て、プソラレンは、２本のDNAヘリックス間に架橋する
ことによって、無秩序な細胞増加を停止する。このこと
は、５−メトキシプソラレンは正常細胞の増加は妨げる
ことなしに、乾癬症の細胞及び癌細胞といった増殖が促
進化されている疾病細胞を選択的に遮断するということ
である。However, in cells infected with psoriasis or cancer, that is, cells in which the increase phenomenon is greatly promoted, the self-correction system does not work. However, for such cells, psoralen arrests unregulated cell expansion by bridging between the two DNA helices. This means that 5-methoxypsoralen selectively blocks disease-promoted diseased cells such as psoriatic cells and cancer cells without interfering with the proliferation of normal cells.

キノコ状真菌症リンパ腫（リンパ細胞の癌）について、
５−メトキシプソラレンを投与してそしてUV・A暴露する
といった治療の結果が良好であったので、本出願人は今
度は皮膚の他の種類の癌または前癌状態病巣、すなわち
表皮細胞の増殖性腫瘍であって間隙液体の細胞はもはや
増殖しないといった例えば基底細胞上皮腫、棘状細胞上
皮腫、ハッチンソンそばかす、化学線性角質増殖、皮膚
黒色腫等について研究することにした。About mushroom fungal lymphoma (cancer of lymph cells)
Given the favorable outcome of treatments such as the administration of 5-methoxypsoralen and the exposure to UVA, the applicant now turns to another type of cancer or precancerous lesion of the skin, namely the proliferation of epidermal cells. I decided to study basal cell epithelioma, spinous cell epithelioma, Hutchinson's freckle, actinic keratoproliferation, cutaneous melanoma, etc., that is a solid tumor and cells in the interstitial fluid no longer grow.

この発想は、日射によってこのような腫瘍が生ずるから
５−メトキシプソラレン及び紫外線の組合せ治療は表皮
増殖性腫瘍の場合には全然得策でないというすっかり定
着している一般的予見に反するものであった。This idea was contrary to the well-established general prediction that the combination treatment of 5-methoxypsoralen and UV rays is not a good idea in the case of epidermal proliferative tumors because such tumors are produced by solar radiation. .

従って、本出願人が５−メトキシプソラレンが新規でそ
して特殊な条件下で投与すると表皮増殖性腫瘍を治ゆす
るということを見出したのは、特に薬量学からいって
も、全く予想外のことである。Therefore, the Applicant has found that 5-methoxypsoralen cures epidermal proliferative tumors when administered under novel and special conditions, which is totally unexpected, especially from the perspective of posology. That is.

この５−メトキシプソラレンの薬理的活性は紫外線に起
因する癌性腫瘍のマウスに局所適用させたときに顕著で
ある。The pharmacological activity of 5-methoxypsoralen is remarkable when it is topically applied to mice with cancerous tumors caused by ultraviolet rays.

局所適用製剤としての、５−メトキシプソラレンの必要
濃度は非常に高く：従来の使用濃度の１０ないし100倍
で、そしてこの濃度の調節は賦形剤により行う。The required concentration of 5-methoxypsoralen as a topically applied formulation is very high: 10 to 100 times the conventionally used concentration, and this concentration is adjusted by the excipient.

５−メトキシプソラレンを1,000ないし10,000ppm含有す
る局所適用製剤の一般毒性を、いろいろな賦形剤を用い
てマウスについて研究していたところ、この有効成分
は、高い投与量でさえも、十分な許容度を有することが
わかった。このことは、５−メトキシプソラレンが８−
メトキシプソラレンに比べてたいへん毒性が低いという
事実と一致する。When the general toxicity of topical formulations containing 1,000 to 10,000 ppm of 5-methoxypsoralen was studied in mice using various excipients, it was shown that this active ingredient is effective even at high doses. It was found to have tolerance. This means that 5-methoxypsoralen is 8-
Consistent with the fact that it is much less toxic than methoxypsoralen.

この、５−メトキシプソラレンの局所投与のために種々
な担体について満足しうることが証明された。次に掲げ
る例は、具体的に説明するためのものだが、これらに限
定されるのではない： ―種々の粘度の純粋黄色ワセリン（フランス薬局方収載
品）、 ―サリチル酸混合黄色ワセリンのような変性黄色ワセリ
ン、 ―鉱油、 ―植物油、特には少数の二重結合を含むエチレン性油、 ―ラノリン、 ―油性連続相エマルジョン、 ―アルコール性溶液、等。This proved satisfactory for various carriers for topical administration of 5-methoxypsoralen. The following examples are intended to be illustrative but not limiting: pure yellow vaseline of various viscosities (listed in the French Pharmacopoeia), modified with salicylic acid mixed yellow vaseline. Yellow petrolatum, mineral oils, vegetable oils, especially ethylenic oils containing a small number of double bonds, lanolin, oily continuous emulsions, alcoholic solutions, etc.

癌細胞は、その細胞膜を厚くするという現象で明らかな
ように、それらの環境に対して強力な防壁を形成するた
め、局所的経路ではその薬剤の組織への浸透はおそくて
困難である。Cancer cells form a strong barrier against their environment, as evidenced by the phenomenon of thickening of their cell membranes, so that penetration of the drug into tissues by the local route is slow and difficult.

本発明において、次のような５−メトキシプソラレン局
所適用製剤浸透薬剤に導くのが有利であることが見出さ
れた： ―ミリスチン酸イソプロピル、 ―ジメチルスルホキシド（DMSO）、等。In the present invention, it has been found to be advantageous to lead to 5-methoxypsoralen topically applied penetrants such as: isopropyl myristate, dimethyl sulfoxide (DMSO), etc.

以下の臨床実験は、純粋黄色ワセリン中５−メトキシプ
ソラレン10,000ppmを含有する製剤を用いて行った。The following clinical experiments were performed with a formulation containing 10,000 ppm 5-methoxypsoralen in pure yellow petrolatum.

有志の患者（それらのうち約100人）のすべては、その
親族にそして本人自身に皮膚癌の前歴があった。彼らは
すべて以前に皮膚癌の切除手術を何回も受けていて、そ
してそれまでのその治療は、これといって癌の再発を阻
止するためのものではなかった。All volunteer patients (about 100 of them) had a history of skin cancer in their relatives and in themselves. All of them had undergone skin cancer resection surgery many times before, and until then their treatment was by no means to prevent the cancer from recurring.

これらの患者の癌または前癌性病巣の種類は、組織学的
に次のように判定された： ―基底細胞上皮腫 ―棘状細胞上皮腫 ―ハッチンソンそばかす ―化学線性角質増殖。The type of cancer or precancerous lesions in these patients was histologically determined as follows: -basal cell epithelioma-spinous cell epithelioma-Hutchinson freckles-actinic keratinization.

これらの患者のうちの何人かには、その片側にはこの治
療を施こし、もう片側は参照のため未処理としておいた
その身体または四肢の両側に効果があらわれた。Some of these patients had an effect on both sides of their body or limb, one side of which received this treatment and the other side left untreated for reference.

選出患者はすべて、他に重大な病気はなかった。All selected patients had no other significant illness.

すべての患者に、次のような処置を、５週間のあいだ行
った： 純粋黄色ワセリンを基剤とする５−メトキシプソラレン
10,000ppm含有の製剤を、１週間に２回腫瘍及びその近
接周囲の健常部位（臨床的に評価される腫瘍の境界を１
ないし２cm超えた部分）に塗布する。塗布後１ないし３
時間に、その患者を５ジュール／cm2ないし１０ジュー
ル／cm2（治療終了時）のエネルギーの紫外線暴露させ
るが、この際暴露１５分前にその製剤をもう一度塗布す
る。５−メトキシプソラレン製剤を塗布した全領域を照
射する。All patients were treated for 5 weeks as follows: Pure yellow petrolatum-based 5-methoxypsoralen
A preparation containing 10,000 ppm was applied twice a week to a tumor and a healthy part in its vicinity (the boundary of the clinically evaluated tumor was
To 2 cm or more). 1 to 3 after application
At that time, the patient is exposed to UV light at an energy of 5 Joules / cm 2 to 10 Joules / cm 2 (at the end of treatment), the formulation being reapplied 15 minutes before exposure. Irradiate the entire area coated with the 5-methoxypsoralen formulation.

次に結果を示す：治療終了時、すなわち６週間以上経過
後に生体組織鏡検を行ったところ、腫瘍癌細胞が全体的
に壊死（並びに正常組織との癒着）を示した。The results are shown below: When biopsy was performed at the end of treatment, that is, after 6 weeks or more, tumor cancer cells showed necrosis (and adhesion with normal tissue) as a whole.

治療後６ケ月毎に新たに生検を実施したところ、３年間
にわたって再発または疾病の残留の徴候はあらわれなか
った。A new biopsy was performed every 6 months after treatment and showed no signs of recurrence or residual disease for 3 years.

薬剤に対する耐性及び照射は申し分なく、すなわち、治
療延期による重大な光毒性のあらわれはみられなかっ
た。ある患者の場合、すぐに消失するものの、局部的に
化学線性紅斑が生じたが、これはその患者が、主として
その皮膚の種類によってより高い感受性を有していたた
めと考えられる。Drug resistance and irradiation were satisfactory, ie no significant phototoxicity due to postponement of treatment. In some patients, local actinic erythema occurred, albeit with immediate disappearance, presumably because the patient was more sensitive, primarily due to his skin type.

このような治療によって総合的に成功した患者は、一般
には、いわゆるＩ型といわれる皮膚の種類で、これは特
に皮膚癌にかかりやすくそして光毒性による影響が顕著
なものであるということに注目するべきである。It is noted that the overall success of patients with such treatments is generally of the so-called type I skin type, which is especially susceptible to skin cancers and is markedly affected by phototoxicity. Should be.

表皮増殖性腫瘍の同様の種類に対する他の臨床実験とし
ては、５−メトキシプソラレンを濃度1,000ないし10,00
0ppmで局所投与することに加え、二重に５−メトキシプ
ソラレンを含有する錠剤を経口投与して続く平均エネル
ギー５ジュール／cm2の紫外線暴露からなる治療を行っ
た。本実験の結果も非常に良好で、癌細胞の全体的な壊
死が観察された。Another clinical trial for a similar type of epidermal proliferative tumor was 5-methoxypsoralen at a concentration of 1,000 to 10,000.
In addition to topical administration at 0 ppm, tablets containing double 5-methoxypsoralen were orally administered followed by a treatment consisting of UV exposure with an average energy of 5 joules / cm 2 . The results of this experiment were also very good, with overall necrosis of the cancer cells observed.

５−メトキシプソラレンは毒性が低いので、癌性腫瘍の
経口的治療のための１日量は400ないし800mgまでも可能
である。照射するエネルギー量よりは有効成分の投与量
を増加する方が常に好ましく、というのは紫外線暴露は
常に１０ジュール／cm2以下で残留するからである。Due to the low toxicity of 5-methoxypsoralen, the daily dose for oral treatment of cancerous tumors can be up to 400-800 mg. It is always preferable to increase the dose of the active ingredient over the amount of energy applied, since UV exposure always remains below 10 joules / cm 2 .

自然経路で効果がある粘膜上の癌性腫瘍の場合にも、紫
外線暴露が真皮の非常に深いところまで透過することを
考慮すれば、前述のような治療をそのまま適用すること
ができる。内部癌性腫瘍の場合は、５−メトキシプソラ
レン投与の後に、深い部位にまで到達するに必要なエネ
ルギーを与える任意の波長の、より透過力のある輻射線
暴露が必要である。Even in the case of a cancerous tumor on the mucous membrane which is effective by the natural route, the above-mentioned treatment can be applied as it is, considering that the UV exposure penetrates to a very deep portion of the dermis. In the case of internal cancerous tumors, more transmissive radiation exposure of any wavelength that provides the energy needed to reach deeper sites is required after 5-methoxypsoralen administration.

Claims (5)

【特許請求の範囲】[Claims] 【請求項１】有効成分として、次式： で表わされる５−メトキシプソラレンを、治療上許容さ
れる担体中1,000ppmないし10,000ppmの濃度で含有する
ことを特徴とする、表皮性増殖癌性腫瘍に対して、局所
適用による光化学的治療用の薬剤。1. The following formula as an active ingredient: For the photochemical treatment by topical application to epidermal proliferative cancerous tumors, which comprises 5-methoxypsoralen represented by the formula (1) in a therapeutically acceptable carrier at a concentration of 1,000 ppm to 10,000 ppm. Drugs. 【請求項２】更に、浸透剤を含有することを特徴とする
特許請求の範囲第１項記載の薬剤。2. The drug according to claim 1, further comprising a penetrant. 【請求項３】その浸透剤が、ジメチルスルホキシド（DM
SO）であることを特徴とする特許請求の範囲第２項記載
の薬剤。3. The penetrant is dimethyl sulfoxide (DM).
The drug according to claim 2, which is SO). 【請求項４】その治療上許容される担体が、黄色ワセリ
ン、鉱油及び植物油、油性連続相エマルジョン、アルコ
ール性溶液等である特許請求の範囲第１ないし第３項い
ずれか１項記載の薬剤。4. The agent according to any one of claims 1 to 3, wherein the therapeutically acceptable carrier is yellow petrolatum, mineral oil and vegetable oil, oily continuous phase emulsion, alcoholic solution and the like. 【請求項５】有効成分として、次式： で表わされる５−メトキシプソラレンを、１錠あたり該
有効成分を200ないし400mg含有する錠剤の形体で含有す
ることを特徴とする、癌性または前癌性腫瘍に対して、
経口的適用による光化学的治療用の薬剤。5. The following formula as an active ingredient: To a cancerous or precancerous tumor characterized by containing 5-methoxypsoralen represented by the following in the form of a tablet containing 200 to 400 mg of the active ingredient per tablet:
A drug for photochemical treatment by oral application.
JP58097768A 1982-04-09 1983-06-01 Drug containing psoralen derivative Expired - Lifetime JPH0653664B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8206262A FR2524801B1 (en) 1982-04-09 1982-04-09 DRUGS CONTAINING A PSORALENE DERIVATIVE
BE0/210731A BE896700A (en) 1982-04-09 1983-05-09 MEDICINAL PRODUCTS CONTAINING A PSORALENE DERIVATIVE.

Publications (2)

Publication Number Publication Date
JPS59222413A JPS59222413A (en) 1984-12-14
JPH0653664B2 true JPH0653664B2 (en) 1994-07-20

Family

ID=36782343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58097768A Expired - Lifetime JPH0653664B2 (en) 1982-04-09 1983-06-01 Drug containing psoralen derivative

Country Status (7)

Country Link
JP (1) JPH0653664B2 (en)
AU (1) AU559029B2 (en)
BE (1) BE896700A (en)
CA (1) CA1205386A (en)
CH (1) CH656801A5 (en)
FR (1) FR2524801B1 (en)
GB (1) GB2140686B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106365D0 (en) * 1991-03-26 1991-05-15 Bioglan Lab Ltd An emollient for use with ultraviolet light
FR2695036B1 (en) * 1992-09-03 1994-10-28 Goupil Jean Jacques Oil containing 5-methoxypsoralen at a concentration of 60 to 100 PPM and its use for the treatment of psoriasis.
US5556612A (en) * 1994-03-15 1996-09-17 The General Hospital Corporation Methods for phototherapeutic treatment of proliferative skin diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2406444A1 (en) * 1977-10-21 1979-05-18 Goupil Jean Jacques 5-Methoxy-psoralen for psoriasis treatment - prepd. from phloroglucinol via mono-methyl ether, 6-hydroxy-4-methoxy-coumaran-3-one and coumaran
LU80347A1 (en) * 1977-10-21 1979-03-16 Goupil J 5-METHOXY-PSORALENE AS A NEW MEDICINAL PRODUCT AND SYNTHESIS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARCINOGENESIS=1981 *

Also Published As

Publication number Publication date
AU1490583A (en) 1984-11-29
JPS59222413A (en) 1984-12-14
AU559029B2 (en) 1987-02-19
BE896700A (en) 1983-09-01
GB2140686B (en) 1986-09-17
CH656801A5 (en) 1986-07-31
FR2524801A1 (en) 1983-10-14
CA1205386A (en) 1986-06-03
GB2140686A (en) 1984-12-05
FR2524801B1 (en) 1985-08-30
GB8315070D0 (en) 1983-07-06

Similar Documents

Publication Publication Date Title
Wolff et al. Photochemotherapy for psoriasis with orally administered methoxsalen
Lowe et al. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen
Robinson et al. Photodynamic therapy: a better treatment for widespread Bowen's disease
Roenigk Jr Photochemotherapy for mycosis fungoides: Long-term follow-up study
EP0295280B1 (en) Use of protoporphyrin and tin mesoporphyrin for the manufacture of a medicament for the treatment of psoriasis
Abel et al. Treatment of palmoplantar psoriasis with topical methoxsalen plus long-wave ultraviolet light
Boer et al. Comparison of phototherapy (UV-B) and photochemotherapy (PUVA) for clearing and maintenance therapy of psoriasis
Cripps et al. Photochemotherapy for psoriasis remission times. Psoralens and UV‐A and combined photochemotherapy with anthralin
Van der Schaar et al. An evaluation of PUVA-therapy for alopecia areata
Mai et al. Childhood vitiligo successfully treated with bath PUVA
Danno et al. Topical 8‐methoxypsoralen photochemotherapy of psoriasis: a clinical study
JPH0653664B2 (en) Drug containing psoralen derivative
US4970230A (en) Drugs containing a psoralene derivative
Brücke et al. Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis
Rampen Hypertrichosis in PUVA‐treated patients
RU2336078C2 (en) Application of porphyrin synthesis substances of for application in phototherapy, as well as for treatment of dermatopathy of arthropathy
US5200425A (en) Drugs containing a psoralene derivative
ES2214066T3 (en) PREPARATION OF KHELLINA FOR THE TOPICAL THERAPY OF PSORIASIS, ITS SUBTIPOS, SPECIAL FORMS, AS WELL AS THE TOPIC THERAPY OF ECZEMAS.
US20080038376A1 (en) Anti-cancer composition and method for using the same
US20030083324A1 (en) Photosensitizing ointment
WO2006085517A1 (en) Ointment preparation or suppository for pdt based on chlorin or porphyrin derivative
Reshad et al. Does UV‐A potentiate ‘short contact’dithranol therapy?
RU2161053C1 (en) Method for applying photodynamic therapy in treating patients having malignant tumors
NIETSCHE Photochemotherapy of psoriasis
Gasior-Chrzan Cellular blue nevus in association with phototherapy